ArticleESMO open2026

Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma.

Y Loriot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.